OVERALL INTERLEUKIN-6 PRODUCTION EXCEEDS 7 MG/DAY IN MULTIPLE-MYELOMA COMPLICATED BY SEPSIS

被引:22
作者
LU, ZY
BRAILLY, H
ROSSI, JF
WIJDENES, J
BATAILLE, R
KLEIN, B
机构
[1] INST BIOL,ONCOGENESE IMMUNOHOHEMATOL LAB,F-44035 NANTES,FRANCE
[2] IMMUNOTECH SA,F-13288 MARSEILLE 9,FRANCE
[3] CLIN VAL DAURELLE,F-34100 MONTPELLIER,FRANCE
[4] CTR REG TRANSFUS SANGUINE,F-25020 BESANCON,FRANCE
[5] SUZHOU MED COLL,DEPT PATHOPHYSIOL,SUZHOU,PEOPLES R CHINA
关键词
IL-6; SEPSIS; MULTIPLE MYELOMA;
D O I
10.1016/S1043-4666(05)80007-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We previously reported that injection of anti-IL-6 monoclonal antibody (mAb) in a patient with multiple myeloma (MM) induced the circulation of high amounts of IL-6 in the form of IL-6/anti-IL-6 monomeric complexes. This made it possible to estimate overall daily IL-6 production in patients in vivo, which had not been achieved in animals or humans before. In this study, estimations are given for a patient with MM who developed Escherichia coli sepsis during anti-IL-6 mAb. During the first 12 days, the overall IL-6 production was estimated at 1.5 to 2.0 μg/day. On day 13, serum IL-6 concentration, in the form of IL-6/anti-IL-6 complexes, increased 1000-fold and was 1.7×106 pg/ml, in relation with the development of E. coli sepsis. Overall IL-6 production was estimated to be greater than 7 mg/day, i.e. 3500 times higher than before sepsis. Serum IL-6 levels in the form of monomeric immune complexes remained very high for 20 days after sepsis indicating the persistence of very high overall IL-6 production (100 to 3500-fold greater than pre-sepsis production). This study demonstrates a considerable and persistent potential for IL-6 production in this patient during and after sepsis. © 1993 Academic Press, Inc.
引用
收藏
页码:578 / 582
页数:5
相关论文
共 15 条
[1]   SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS [J].
BATAILLE, R ;
JOURDAN, M ;
ZHANG, XG ;
KLEIN, B .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) :2008-2011
[2]  
BAUMANN H, 1988, J BIOL CHEM, V263, P17390
[3]  
BREEN EC, 1990, J IMMUNOL, V144, P480
[4]   PLASMA-CLEARANCE, ORGAN DISTRIBUTION AND TARGET-CELLS OF INTERLEUKIN-6 HEPATOCYTE-STIMULATING FACTOR IN THE RAT [J].
CASTELL, JV ;
GEIGER, T ;
GROSS, V ;
ANDUS, T ;
WALTER, E ;
HIRANO, T ;
KISHIMOTO, T ;
HEINRICH, PC .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 177 (02) :357-361
[5]   ACUTE-PHASE RESPONSE OF HUMAN HEPATOCYTES - REGULATION OF ACUTE-PHASE PROTEIN-SYNTHESIS BY INTERLEUKIN-6 [J].
CASTELL, JV ;
GOMEZLECHON, MJ ;
DAVID, M ;
FABRA, R ;
TRULLENQUE, R ;
HEINRICH, PC .
HEPATOLOGY, 1990, 12 (05) :1179-1186
[6]  
DELAGE M, 1991, METHODS IMMUNOLOGIC
[7]  
HELFGOTT DC, 1989, J IMMUNOL, V142, P948
[8]   MOLECULAR-CLONING AND EXPRESSION OF AN IL-6 SIGNAL TRANSDUCER, GP130 [J].
HIBI, M ;
MURAKAMI, M ;
SAITO, M ;
HIRANO, T ;
TAGA, T ;
KISHIMOTO, T .
CELL, 1990, 63 (06) :1149-1157
[9]   INTERLEUKIN-6 IN SYNOVIAL-FLUID AND SERUM OF PATIENTS WITH RHEUMATOID-ARTHRITIS AND OTHER INFLAMMATORY ARTHRITIDES [J].
HOUSSIAU, FA ;
DEVOGELAER, JP ;
VANDAMME, J ;
DEDEUXCHAISNES, CN ;
VANSNICK, J .
ARTHRITIS AND RHEUMATISM, 1988, 31 (06) :784-788
[10]  
KLEIN B, 1991, BLOOD, V78, P1198